Atevirdine

Drug Profile

Atevirdine

Alternative Names: Atevirdine mesylate; U 85961; U 87201; U 87201E

Latest Information Update: 06 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacia Corporation
  • Class Antiretrovirals; Piperazines
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 19 Feb 1999 A study (ACTG 187) has been added to the pharmacokinetics, therapeutic trials, antimicrobial activities and adverse events section
  • 11 Apr 1995 Two studies have been added to the pharmacokinetics section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top